Article | September 29, 2022

Modernizing Your Cell & Gene Therapy Manufacturing Operations

By James Jardine


Cell and gene therapy (CGT) has grown from being considered a niche sector of biopharma, into the most rapidly expanding and investor-enticing product pipeline in the life sciences. With 1,300 companies actively involved in CGT manufacturing and 11 gene therapy medicinal products with valid marketing authorization, the question now becomes how to bring those innovative therapies to market.

Here we learn the importance of possessing a streamlined processes, flexible systems, and the scalability and manufacturing capacity to adequately support production, clinical trials, and approval processes. We also explore the importance of new cell and gene therapy software solutions and the role of the cell and gene therapy CMO.



Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online